PatientsVille.com Logo

Medical and Scandishake

PatientsVille

Medical Symptoms and Causes

Every day, around the clock, people who work in the health care industry provide care for millions of people, from newborns to the very ill. In fact, the health care industry is one of largest providers of jobs in the United States. Many health jobs are in hospitals. Others are in nursing homes, doctors' offices, dentists' offices, outpatient clinics and laboratories.

To work in a health occupation, you often must have special training. Some, like doctors, must have more than 4 years of college.

Bureau of Labor Statistics

Check out the latest treatments for medical

medical treatment research studies

Scandishake clinical trials, surveys and public health registries


Find Drug Side Effect reports



Scandishake Side Effects

Cardiac Disorder (4)
Cerebral Atrophy (4)
Dysphagia (3)
Multiple System Atrophy (2)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

I am BiomedicalINGINEER in Abidjan IVORY COST (WEST AFRICA) My device is HFQ-8000P SERIAL NO 564 <strong>TREX MEDICAL SYSTEMS CORP</strong>and i have an problem.an error&nbs

100ml cassettes finishes before actual time, but the cassettes was correctly filled with the required volume.

A complete nightmare!

An elderly friend received a heart valve in 1996, serial number 60310492 , model number V 21AHPJ-505. She is wondering what is the life of the valve and would she need to have it replaced. She is 82 years old.

Came out worse than when I went in: Demoralized, bruised by the used of excess force, sexually violated and refused medical treatment (uninsured). I was told that my pain was not their concern and a medical doctor would not being examining me. Afte

Could you please provide me the price for : spinal needle No 22GA ? i am looking forward to hearing from you soonest

Flexible tip guide wire for oesophageal strictures dilatation

God bless.We pray for you.From Kenya Africa

Hello Pls let m know year of manufacturing software release and when available Karim Almimar Karimalmimar@yahoo.com

I am BiomedicalINGINEER in Abidjan IVORY COST (WEST AFRICA) My device is HFQ-8000P SERIAL NO 564 <strong>TREX MEDICAL SYSTEMS CORP</strong>and i have an problem.an error&nbs

<span style='color: #808080;'><b>i was given a flu shot on 11/18/10 the medical asst did the injection higher than i have ever had in the past. she injected right on the bone. the pain i have is horrible. i had an exray. (no foreign body)

...this drug should not be prescribed for use out of medical insttitutions and 24/7 MD watch

42 y.o. female, no medical hx. of urinary incontinence until the use of Mucinex D 1200mg po bid. Resolved after med. being discontinued.

66 yearr old male living in Winnipeg, MB Cannada. Ialso have other medical problems besides this one. Like Epilepsy, Antidepressant,Migraines,Chloresterol,Klinefelter's Syndrome,High blood pressure, Shortness of breath, HIV, ITCHING.

After Demerol was pushed through my IV. Almost immediately I had a hard time breathing, gasping for breath. Very sweaty and itchy and lightheaded. My blood pressure dropped and medical reports say that I did not have any BP at all at one point. They

An injection of toradol in hattiesburg Forrest general Hospital resulted in complete Kidney failure with 5 days in hospital. medical records are available if proof is needed. recovered

As the damage continues to be ignored by the medical community in the entire world and by the FDA... As patients with 'Post-Lipiodol Arachnoiditis' are singled out wherever they are in the world, the younger ones in the 3rd world countries and East-E

Because as a medical profession i should know about

Came out worse than when I went in: Demoralized, bruised by the used of excess force, sexually violated and refused medical treatment (uninsured). I was told that my pain was not their concern and a medical doctor would not being examining me. Afte

Medical Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening
Condition: Prostate Cancer
Intervention: Behavioral: Computer-based prostate cancer screening decision aid
Outcome Measures: 1.Informed Decision Making;   1.Satisfaction with Decision Making Process and Decision;   2.Decisional conflict;   *All measures assessed at baseline and follow up survey and will be completed by month 6 of year 3 of the study
2 Recruiting Simulation-based Curriculum to Enhance Culture of Safety in Operating Rooms
Condition: Surgery
Intervention: Other: Simulation - based curriculum
Outcome Measures: Frequency of surgical interventions having at least on communication failure with a consequence;   Compliance to the safety checklist in the operating room;   6 items survey estimating teamwork quality;   Number of adverse events occuring in the OR declared to the institution;   Surgical Apgar score;   Nature of communication failure and consequences;   rate of communication failures;   Survey on safety culture for employees working in the OR;   Count of team members and number of passage in the OR
3 Recruiting The Impact of Prenatal Short Messages (SMS) on Maternal and Newborn Health
Conditions: Short Message Service;   Text Messaging
Interventions: Behavioral: Good household prenatal practice;   Behavioral: Care seeking;   Behavioral: Full bank of SMS
Outcome Measures: Newborn health;   Neonatal Adverse Outcome Indicator (NAOI);   Actual number of prenatal visits over expected visits;   Uptake of government-subsidized programs;   C-section rate;   Maternal health;   Near-miss
4 Unknown  Hospital Admissions in Children Aged 3 Months to 5 Years Presenting With Fever to the Emergency Department
Condition: Fever
Intervention:
Outcome Measure: Hospital admission
5 Recruiting Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
Condition: Herpes Zoster
Intervention: Other: Data collection
Outcome Measures: Occurrence of HZ cases as recorded per participating centre, overall and within a specific age group and gender.;   Occurrence of PHN, i.e. persistence of HZ-related pain.;   Anamnestic information, clinical parameters and complications related to HZ.;   Direct medical, direct non-medical and indirect costs related to HZ.;   Pain assessment in HZ patients.;   Quality of life assessment in HZ patients.;   Direct medical, direct non-medical and indirect costs related to PHN.;   Pain assessment in PHN patients.;   Quality of life assessment in PHN patients.
6 Recruiting A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above
Condition: Herpes Zoster
Intervention: Other: Data collection
Outcome Measures: Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age.;   Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study.;   Occurrence of HZ-associated hospitalisations.;   Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study.;   Anamnestic information, clinical parameters and complications related to HZ.;   Direct medical, direct non-medical and indirect costs related to HZ.;   Quality of life (QoL) assessment in HZ subjects.;   Direct medical, direct non-medical and indirect costs related to PHN.;   QoL assessment in PHN subjects.;   Impact of the following factors on the development of PHN: - age, - gender, - concomitant disease, - current immunosuppressive therapy, - HZ severity at first consultation, - timing of initiation of treatment with antiviral agent etc.
7 Recruiting Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain
Condition: Herpes Zoster
Intervention: Other: Data collection
Outcome Measures: Total number of HZ cases as recorded per participating practice, overall and within a specific age group and gender.;   Occurrence of PHN, i.e. persistence of HZ-related pain.;   Anamnestic information, clinical parameters and complications related to HZ.;   Direct medical, direct non-medical and indirect costs related to HZ.;   Pain assessment in HZ subjects.;   Quality of life assessment in HZ subjects;   Direct medical, direct non-medical and indirect costs related to PHN.;   Pain assessment in PHN subjects.;   Quality of life assessment in PHN subjects.
8 Unknown  Imodium Syrup Versus Imodium Tablets for Faecal Incontinence
Condition: Fecal Incontinence
Interventions: Drug: Imodium (Loperamide Hydrochloride) syrup;   Drug: Imodium (Loperamide hydrochloride) tablets
Outcome Measures: To evaluate the use of imodium as tablets or syrup in the treatment of faecal incontinence in order to improve the scores of patients with faecal incontinence as seen with continence and quality of life questionnaires;   To reduce to number of patients suffering from faecal incontinence;   Number of episodes of total, urge and passive incontinence;   Total number of patient incontinent days;   Use of pads and other medications;   Ability to defer defaecation;   Adverse effects relating to medication;   Determining the direct medical costs, direct non-medical costs, indirect non-medical costs associated with the treatment of Faecal incontinence, and cost effectiveness of treatment with syrup and tablets
9 Not yet recruiting Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care
Condition: HIV
Interventions: Behavioral: FAmily-CEntered Advance Care Planning;   Behavioral: Healthy Living Control
Outcome Measures: Statement of Treatment Preferences;   Lyon Advance Care Planning Survey (Patient and Surrogate Version);   Palliative Care Outcome Scale (POS);   Medical Outcomes Study-HIV (MOS-HIV)
10 Recruiting Longitudinal Pediatric Palliative Care: Quality of Life & Spiritual Struggle
Condition: HIV
Interventions: Behavioral: FAmily CEntered (FACE) ACP;   Behavioral: Healthy Living Control
Outcome Measures: congruence in treatment preferences;   QOL;   Utilization of hospitalization;   Utilization of dialysis
11 Recruiting Screening, Brief Intervention, and Referral to Treatment in Primary Care
Conditions: Diabetes Mellitus, Type 2;   Substance-related Disorders
Interventions: Behavioral: Referral to Treatment;   Behavioral: Brief Intervention
Outcome Measures: Change in drug use status or frequency;   Change in treatment use status for drug use problems;   Change in cigarette smoking status and nicotine dependence;   Change in alcohol use status;   Change in treatment use status for alcohol use problems;   Change in medication adherence;   Rate of healthcare services utilization;   Incidence of micro-and macrovascular outcomes;   Patient-reported global health scale scores
12 Recruiting Tinnitus Retraining Therapy Trial
Condition: Subjective Tinnitus
Interventions: Device: Conventional sound generator (SG);   Device: Placebo sound generator (placebo SG);   Behavioral: Standard of Care (SC);   Behavioral: Directive Counseling (DC)
Outcome Measures: Change in score on the Tinnitus Questionnaire (TQ);   Change in TQ sub-scale scores;   Change in Tinnitus Handicap Inventory (THI) score;   Change in Tinnitus Functional Index (TFI) score;   Change in TRT Interview Visual Analogue scales;   Change in Digit Symbol Substitution Test (DSST);   Change in psychoacoustic variables;   Hearing Handicap Inventory (HHI)
13 Not yet recruiting MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study
Condition: Contraception
Intervention: Drug: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
Outcome Measures: Percentage continuation rate of LNG IUS at end of observation period;   Percentage of Women with user satisfaction scoring somewhat satisfied to very satisfied;   Cumulative discontinuation rate for pregnancy;   Cumulative discontinuation rate for other medical reasons;   Cumulative discontinuation rate for non-medical reasons;   Mean percentage of women with amenorrhea;   Mean percent of women with spotting, inter-menstrual bleeding;   Distribution of contraceptive usage patterns;   Incidence rate of drug-related adverse events
14 Recruiting Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy
Conditions: Cerebral Palsy Children;   Children With Traumatic Brain Injury;   Mental Handicap;   Delayed Speech Development
Intervention: Drug: Cerebrolysin (Nerve growth factor)
Outcome Measure: neurodevelopment
15 Not yet recruiting Effectiveness and Cost-effectiveness of a Telemonitoring Program for Diabetic People at Home
Condition: Type 2 Diabetes
Interventions: Other: telemonitoring;   Other: Usual care
Outcome Measures: To assess effectiveness of our telemonitoring program in Diabetes care, HbA1C assays will be compared between the two groups.The change of HbA1c between day 0, month 1,month 3, month 6, month 9 and month 12;   Assessment efficacy of our program by the measure of HbA1C will;   Questionnaires will be given to patients to assess the improvement of nutritional knowledge;   Food inquiries will be given to patients to assess the improvement of eating habits;   Questionnaires will be given to patients to assess the physical activity practice;   Waist circumference will be measured to assess the body composition, BMI (Body Mass Index),;   The self-monitoring blood glucose books will be copied to assess mean of blood glycaemia;   A blood sample will be collected to assess lipid status;   Two questionnaires will be given to patients to assess quality of life of patients;   A cost-effectiveness ratio and a markov modelisation will be realized to assess the economic aspects;   For the telemonitoring arm, assessment of food behavior through meals registered with the Nutri-Educ software;   For the telemonitoring arm, assessment of nutritional knowledge through rate of good choices playing games of Nutri-Kiosk software;   For the telemonitoring arm, assessment of physical activity declared through Acti-Kiosk software and measures collected with the pedometer (number of steps, number of stairs climbed up);   For the telemonitoring arm, measure of weight, fat rate and lean rate collected with the balance;   For the telemonitoring arm, means of glycaemia collected with the self-monitoring blood glucose device;   For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the patients with the number and time of connections and a questionnaire;   For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections;   For the telemonitoring arm, acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections leading to a medical decision (phone call or medical appointment) and a questionnaire
16 Recruiting Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage
Conditions: Cerebral Ischemia;   Subarachnoid Hemorrhage
Intervention: Other: Induced hypertension
Outcome Measures: The main outcome measurement will be the modified Rankin scale at 3 months after the SAH, compared between patients who were randomized to induced hypertension and patients who were randomized to no induced hypertension.;   Related to treatment failure: proportion of patients in the induced hypertension group in which induced hypertension did not give clinical improvement of symptoms of DCI within 24 hours;   Related to the functional condition: Case fatality 30 days after SAH;   Related to the functional condition, activities of daily living (ADL), three months after the SAH assessed with the Barthel Index.;   Related to the functional condition: quality of life, three months after the SAH, estimated with the Stroke Specific Quality of Life Scale (SSQoL-12-NL).;   Related to the functional condition: anxiety and depression, three months after the SAH, assessed with the Hospital Anxiety and Depression Scale (HADS).;   Related to the functional condition: cognitive functioning, three months after the SAH, evaluated by the Cognitive Failures Questionnaire (CFQ).;   Related to adverse effects: complications related to insertion of a central venous catheter or intra-arterial catheter (including local haemorrhage and pneumothorax).;   Related to adverse effects: intracranial complications related to induced hypertension (such as exacerbation of cerebral oedema, hemorrhagic infarction and bleeding of an asymptomatic aneurysm).;   Related to adverse effects± • Systemic complications related to induced hypertension (including cardiac rhythm disorders, low cardiac output state and cardiac ischemia).;   In selected centres: Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the intervention and the control groups 24-36 hours after the start of the study (i.e. CTP-2);   Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the perfusion CT-scan (at baseline, the moment of deterioration, i.e. CTP-1) and the second perfusion CT-scan (CTP-2) within the same patients.;   Direct medical costs of used health care resources and indirect, non-medical costs of lost productivity, will be compared between the two arms of the trial, twelve months after the SAH.
17 Recruiting Neurofeedback for Fibromyalgia
Condition: Fibromyalgia
Intervention: Device: EEG-NF
Outcome Measures: Pain;   Sleep Quality
18 Recruiting Hypertension of Our Patients: Knowledge, Control, Comorbidity
Condition: Hypertension
Intervention:
Outcome Measure: percentage of patients knowing the blood pressure target
19 Recruiting Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Cognitive Deficits;   Stress, Psychological
Interventions: Behavioral: Cognitive Behavioural Therapy;   Behavioral: Aerobic Exercise
Outcome Measures: Change from Baseline in General Health Questionnaire (GHQ-28) at 12 Weeks;   Change from Baseline in the Minimal Assessment of Cognitive Function in MS at 12 Weeks
20 Unknown  Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC)
Condition: Carcinoma, Basal Cell
Intervention:
Outcome Measures: Cost-utility ratio;   2 and 5 years survival